Phase I study of peptide-cocktail vaccination for HCV-positive patients with liver cancer who have undergone radical therapy.
Phase 1
- Conditions
- liver cancer
- Registration Number
- JPRN-UMIN000003773
- Lead Sponsor
- Kurume University Cancer Vaccine Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 3
Inclusion Criteria
Not provided
Exclusion Criteria
The following patients must be excluded: 1) Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disturbance of coagulation). 2)Patients with multiple active cancers 3)Patients suspected with immunodeficiency and opportunistic infection. 4) Patients with the past history of severe allergic reactions. 5)Patients who are during pregnancy, lactation expectant, and desiring future fertility. 6)Patients with a score II or more of hepatic encephalopathy. 7) Patients who are judged inappropriate for the clinical trial by doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety, to evaluate with CTCAE v4.0
- Secondary Outcome Measures
Name Time Method Immunological responses (anti-peptide IgG)